

**North of Tyne and Gateshead
Area Prescribing Committee**
www.northoftyneapc.nhs.uk

Tuesday 1th October 2017.

Room 4, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park. 12.30pm

AGENDA

1.	Apologies for absence	
2.	Declarations of interest <ul style="list-style-type: none"> • 2017 declarations due 	Enc.1.
3.	Appeal against previous decision <ul style="list-style-type: none"> • Insulin Degludec – Nicola Leech <ul style="list-style-type: none"> ○ Original application(s) ○ Refusal notification ○ Supplementary information including <ul style="list-style-type: none"> • Appeal presentation power point • Birmingham, Sandwell, Solihull and environs Area Prescribing Committee (BSSE APC) approval • Tresiba Budget impact modelling • JAMA paper 2017 – Lane et al. • Degludec audit write up • Email summary 	Enc. 2a & 2b Enc.3. Enc.4a. Enc.4b. Enc.4c. Enc.4d. Enc.4e. Enc.4f.
4.	Minutes from the meeting(v2) 11/07/17 Decision summary (v2) from 11/07/17	Enc.5. Enc.6.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> • July • September update 	Email 25/07/17 Enc.7.
7.	Report from the Formulary sub-group <ul style="list-style-type: none"> • Draft minutes from meeting held on 7/09/17 • Decision summary from meeting held on 7/09/17 	Enc.8. Enc.9.
8.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> • Draft Minutes from meeting on 13/09/17 • Guideline(s) for approval <ul style="list-style-type: none"> ○ Menopause guideline – minor update ○ Blood Glucose Monitoring – minor update ○ Hypertension Guideline – 2017 update ○ Kidney Guidelines – minor update • Shared Care Guideline(s) for approval <ul style="list-style-type: none"> ○ Guanfacine Shared Care Guidance for the Management of ADHD in Children and Young People ○ Ketamine in Palliative Care – update ○ Shared Care Guidelines for the Use of Dronedarone - update • Information leaflets for approval <ul style="list-style-type: none"> ○ Acetylcholinesterase inhibitors: information for 	Enc.10. Enc.11. Enc.12. Enc.13. Email 9/10/17 Enc.14. Enc.15. Enc.16. Enc.17.

	<ul style="list-style-type: none"> primary care – update <ul style="list-style-type: none"> o Memantine: information for primary care - update • Guideline(s) and information sheets for removal <ul style="list-style-type: none"> o attachment 	Enc.18. Enc.19.
9.	<p>Appeal against previous decisions (2pm)</p> <ul style="list-style-type: none"> • Safinamide – Naomi Warren <ul style="list-style-type: none"> o Original application o Refusal notification o Email of support from Richard Athey at QE 	Enc.20. Enc.21. Enc.22.
10.	<p>Avastin in wet AMD</p> <ul style="list-style-type: none"> • Policy for the treatment of age-related wet AMD agreed by Northern CCGs • DH original letter to NHS Clinical Commissioners March 2015 • NESPM's email to David Hambleton and reply 	Enc.23. Enc.24. Enc.25.
11.	Role of CCG prescribing forum	Graham Syers
12.	Optimising anticoagulation pathways in Newcastle- joint AHSN NGCCG NUTHFT project update	Neil Morris
13.	<p>Previously circulated</p> <ul style="list-style-type: none"> • NHS England consultation on items of limited value https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed/ • Regional self-care project 	Email 31/07/17 Email 31/07/17
14.	RMOCs	
15.	<p>Northern (NHS) Treatment Advisory Group (NTAG).</p> <p>The following recommendations were finalised by NTAG at their meeting on the 29/09/17 and are now available on the website:</p> <ul style="list-style-type: none"> • Paliperidone long acting injection (Xeplion®) and Paliperidone 3 monthly injection (Trevicta®) Janssen-Cilag for schizophrenia. • Updated guidance on the use of long-acting antipsychotic injections in the North of England. • Liraglutide (Saxenda®) for treatment of obesity – negative appraisal. • Northern Treatment Advisory Group: 3rd Annual Report, June 2017 	Enc.26. Enc.27. Enc.28. Enc.29.

16.	<p>NICE Technology Appraisals published since last meeting - formulary to be amended to reflect the following:</p> <ul style="list-style-type: none"> • HST6 Asfotase alfa for treating paediatric-onset hypophosphatasia • TA452 Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) • TA453 Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) • TA454 Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) • TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people • TA456 Ustekinumab for moderately to severely active Crohn's disease after previous treatment • TA457 Carfilzomib for previously treated multiple myeloma • TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane • TA459 Collagenase clostridium histolyticum for treating Dupuytren's contracture • TA460 Adalimumab and dexamethasone for treating non-infectious uveitis • TA461 Roflumilast for treating chronic obstructive pulmonary disease • TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma • TA463 Cabozantinib for previously treated advanced renal cell carcinoma • TA464 Bisphosphonates for treating osteoporosis • TA465 Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma • TA466 Baricitinib for moderate to severe rheumatoid arthritis • TA467 Holoclar for treating limbal stem cell deficiency after eye burns • TA468 Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) • TA469 Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) • TA470 Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) • TA471 Eluxadolone for treating irritable bowel syndrome with diarrhea • TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab • TA473 Eluxadolone for treating irritable bowel syndrome with diarrhoea • TA474 Sorafenib for treating advanced hepatocellular carcinoma • TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis • TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer • TA477 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee • TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma • TA479 Reslizumab for treating severe eosinophilic asthma 	
-----	--	--

17.	<p>NHS England Specialised Services</p> <ul style="list-style-type: none"> • SSC1745 - NICE Technology Appraisal 441: Daclizumab for treating relapsing–remitting multiple sclerosis • SSC1745 – EMA letter Daclizumab for treating relapsing–remitting multiple sclerosis liver safety • SSC1746 (Updated) - NICE Technology Appraisal 443: Obeticholic acid for treating primary biliary cholangitis • SSC1760 -National Framework Agreement for Human Immunoglobulins • SSC1762 - NICE Technology Appraisal Final Appraisal Determination: Cabozantinib for the treatment of renal cell carcinoma [TA10075] • SSC1763 - Technology Appraisal 448: Etelcalcetide for treating secondary hyperparathyroidism • SSC1764: Clarification statement re National Framework Agreement for Immunoglobulins SSC1760 • SSC1765 - Update on the HIV Switch Initiatives (Anti-Retroviral Therapies). Supplementary information to SSC1632, SSC1650 & SSC1681 (National Anti-Retroviral Therapy Commissioning for Value 2016-2018) • SSC1766 - Anti-retroviral drugs for treatment of young people (aged 6-12 years of age) with diagnosed HIV: Reimbursement of Dolutegravir in paediatric patients under existing Dolutegravir Clinical Commissioning Policy (Ref: NHS England: B06/P/a) • SSC1767 - NICE Technology Appraisal Final Appraisal Determination: Paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) with gemcitabine for untreated metastatic pancreatic cancer • SSC1768 - Urgent Clinical Commissioning Policy Statement (170018/P): Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Biogen Access Scheme • SSC1769 - NICE Technology Appraisal 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma • SSC1771 - Abiraterone for hormone-sensitive metastatic prostate cancer • SSC1772 - NICE Technology Appraisal Final Appraisal Determination: sorafenib for the treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A • SSC1773 - NICE Technology Appraisal Final Appraisal Determination: Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) • SSC1774 - NICE Technology Appraisal Final Appraisal Determination: Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma • SSC 1775 - NICE Highly Specialised Technology HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia • SSC1776 - Biosimilar Rituximab • SSC1777 - Commissioning of Palivizumab (To Reduce the Risk of RSV in High Risk Infants) for the 2017 Vaccination Season • SSC1779 - NICE Technology Appraisal Final Appraisal Determination: Brentuximab vedotin for treating relapsed 	Enc.30 .
-----	--	----------

	<p>or refractory systemic anaplastic large cell lymphoma</p> <ul style="list-style-type: none"> • SSC1780 - NICE Technology Appraisal 460: Adalimumab for treating non-infectious uveitis • SSC1781 - Technology Appraisal 467: Holoclar for treating limbal stem cell deficiency after eye burns • SSC1782 - Early Access to Medicines Scheme – Alectinib as monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) • SSC1783 - NICE Technology Appraisal 473: Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (review of TA172) • SSC1784 - NHS England Policy for Urgent Cases • SSC1785 - NICE Highly Specialised Technology 5: Eliglustat for treating type 1 Gaucher disease • SSC1787 Nivolumab for previously treated non-small-cell lung cancer - Provider Letter • SSC1788 - NICE Technology Appraisal 446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma • SSC1789 - NICE Technology Appraisal 450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia • SSC1790 - NICE Technology Appraisal 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia • SSC1791 - NICE Technology Appraisal 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease • SSC1792 - Anti-retroviral drugs for treatment of HIV: Reimbursement of Raltegravir Once Daily Formulation 									
18.	<p>Chairman's action</p> <ul style="list-style-type: none"> • Blood glucose monitoring guidance – 2017 update 	Email 8/8/17. On website								
19.	Any other business									
20.	<p>Date and time of next meetings:</p> <table border="1" data-bbox="204 1458 1120 1653"> <tr> <td>Tuesday, 9th January 2018</td> <td>12:30 pm</td> </tr> <tr> <td>Tuesday, 10th April 2018</td> <td>13:00 pm</td> </tr> <tr> <td>Tuesday, 10th July 2018</td> <td>12:30 pm</td> </tr> <tr> <td>Tuesday, 9th October 2018</td> <td>12:30 pm</td> </tr> </table> <p>Cobalt Conference Suite, Room 3</p> <p>Northumbria Healthcare NHS Foundation Trust Northumbria House 7-8 Silver Fox Way Cobalt Business Park North Shields NE27 0QJ</p>	Tuesday, 9 th January 2018	12:30 pm	Tuesday, 10 th April 2018	13:00 pm	Tuesday, 10 th July 2018	12:30 pm	Tuesday, 9 th October 2018	12:30 pm	
Tuesday, 9 th January 2018	12:30 pm									
Tuesday, 10 th April 2018	13:00 pm									
Tuesday, 10 th July 2018	12:30 pm									
Tuesday, 9 th October 2018	12:30 pm									